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ABSTRACT
Introduction: Nowadays, all over the world the requirements for drug quality have become more and more 
strict and its evaluation is one of the most important tasks. Usually, input quality control of medicines and 
other groups of goods is carried out organoleptically (mainly visually) by authorized people from pharma-
ceutical establishments. Primary packaging is one of the most critical components in this process, because 
it strongly influences the possibility of visual control of goods and, of course, it should be transparent. 
The aim of this article was to analyze primary packaging of some drugs and the possibility of their identifi-
cation and quality evaluation.
Materials and Methods: Objects of this study were primary packages of 65 randomly chosen drugs pro-
duced by some leading manufacturers in different dosage forms. Inspection analysis of the quality of the 
researched medicinal products was provided in 8 steps: checking of the accompanying documents, check-
ing the quantity of the goods, organoleptic control of packaging, checking of labeling, checking of barcodes, 
checking of completeness, visual control of a product, accompanying documentation for the intake of the 
goods.
Results and Conclusion: All investigated drugs passed the first 6 stages of inspection analysis positively. 
46 samples out of 65 (or 71%) could not be visually controlled (stage 7) and their appearance was impossible 
to check because of the non-transparency of the containers. When separated into different forms, the dis-
tribution is the following: 53% of studied tablet drugs, 88% of eye drops and 100% of suppositories cannot 
be evaluated visually.
Keywords: visual inspection, drugs, packaging materials, primary packaging, quality
INTRODUCTION
The range of pharmaceutical products on the 
Ukrainian market is formed by both domestic and 
imported drugs. Nowadays, consumer requirements 
for drug quality are significantly increasing. Due to 
economical imbalance substantial reduction in the 
production volume has occured. Meanwhile, the 
market is full of low-quality, substandard and coun-
terfeit goods. According to the data of the Organi-
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zation for Economic Co-operation and Development 
(OECD) the international trade of counterfeit goods 
reaches $200 billion per year (1). A significant decline 
in the living standards has affected their entry into 
the domestic market. Most buyers cannot afford ex-
pensive brand drugs, which is why counterfeit drugs 
is directed to them. As a consequence, in developing 
countries they can take up to 35% of the pharmaceu-
tical market (2).
Use of such products is associated with a sig-
nificant risk for the life and health of the consumers. 
Counterfeit drugs are the major cause of morbidity, 
mortality, and loss of confidence in the healthcare 
system (3). According to data (4), most of the coun-
terfeit reports are related to antibiotics, antiprotozo-
als, hormones, and steroids. Therefore, the challenge 
of supplying the domestic market with high-quality 
drugs is very urgent now. 
Manufacturers have to develop more and more 
advanced methods to prevent counterfeiting of their 
own goods. These means can be divided into two 
main groups: visible and hidden ones. The first group 
involves advanced barcodes, holograms, three-di-
mensional images, special inks, watermarks (5–8). 
The second group includes radio-frequency identifi-
cation (RFID) tags, UV-sensitive hidden paints, bio-
metric fingerprints, etc. (8–12). It’s important for all 
of these means to be able to control the goods and 
their authenticity during the entire supply chain and 
finally in pharmacies.
The quality level of the products is a relative 
characteristic based on a comparison of actual indi-
cators of the product quality with standard ones.
Nowadays, all over the world consumer re-
quirements for drug quality have become much 
stricter and its determination and methods of its ex-
pression are some of the most important tasks of our 
time (13).
The quantitative characteristics of the products 
are characterized by quality parameters. It’s possi-
ble to define either single or comprehensive index-
es. Comprehensive evaluation characterizes the over-
all quality level of the tested product and allows the 
drawing of conclusions about the conformity of its 
properties to the consumer needs and the require-
ments of normative documents (14,15). 
Legal regulation of the drug control procedures 
in Ukraine is provided by President Decrees and le-
gal acts of the Ministries, which adopt National strat-
egies, concepts and programs (16–22). Currently, 
there are four supplements to the State Pharmaco-
poeia of Ukraine (in 2004, 2008, 2009, 2011), among 
which the 1st supplement which establishes the re-
quirements for  drugs containers (23).
At present, quality control of medicinal prod-
ucts is carried out under order № 677 of the Minis-
try of Public Health of Ukraine dated 29.09.2014 “On 
approval of the rules for quality control of medicinal 
products in wholesale and retail trade” (22).
Input quality control of medicines in retail 
and wholesale trade is carried out organoleptically 
(mainly visually) by authorized people from phar-
maceutical establishments having a license for pro-
viding business activities in the wholesale and retail 
trade of medicines. The visual method is based on 
the use of information obtained by the senses – sight, 
hearing, smell and touch.
The organoleptic method has certain advantag-
es. First, it does not require special instruments, de-
vices, and complex equipment. Second, it provides 
fast indicating and is always used first, even some-
times eliminating the need for measuring methods 
especially when taste, flavors, smells, colors, consis-
tence of perfumes and cosmetics are tested. Its main 
disadvantage is subjectivity. In order to reduce it one 
uses quantitative methods to evaluate some quality 
parameters (24). 
At the reception of goods an authorized person 
checks:
 ❖ compliance of the drugs to shipping documents 
regarding quantity, dosage, batch numbers, ex-
pire dates, registration status, name, dosage 
form, manufacturer. Each batch of a drug must 
be accompanied with copies of the batch qual-
ity certificate which is given by the manufac-
turer (for imported medicines - by the foreign 
manufacturer together with a stamped conclu-
sion about the quality of the imported drug giv-
en in Ukraine);
 ❖ labeling of the secondary and primary packag-
ing, presence of a leaflet for the drug specifying 
instructions for its use, appearance and integri-
ty of the secondary packaging, uniformity, ab-
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sence of damages, quality of the packaging ma-
terials. If necessary, drugs are tested after open-
ing the package, for their size, shape, color, ho-
mogeneity, quantity of units in the package, 
presence or absence of impurities.
If the result from the input control is positive, 
an authorized person gives permission for the distri-
bution of the drug batches obtained.
In case of any doubt about the quality of the 
medicines during the performance of a visual in-
spection, an authorized person takes samples from 
the suspicious drugs and sends them to the Territo-
rial Inspectorate for Drug Quality and Safety Con-
trol to provide full laboratory examination. Until ob-
taining the conclusion about the quality of the suspi-
cious batches they are kept within a quarantined area 
(premise), separately from other products. 
Based on the above-mentioned, it can be con-
cluded that the inspection analysis lies in the evalu-
ation of shipping documents, labeling, and appear-
ance of secondary and sometimes primary packag-
ing, but the organoleptic analysis of certain drugs is 
made only when required. This suggests that quality 
evaluation of drug forms may be skipped.
Therefore, most publications about the falsi-
fication of medicines are focused on assessing the 
quality of the secondary packaging materials and la-
beling (25–27).
In practice, only a few studies were conducted 
and several papers about the effects of the primary 
packaging materials on the organoleptic properties 
of drugs during input control were published (28,29).
Thus, there is a need for a comprehensive in-
spection analysis to determine the quality of medi-
cines produced in Ukraine and abroad.
Sale of medicines and medical devices is not 
possible without their pre-packaging.
Primary packaging is one of the most impor-
tant components and functions of the drug produc-
tion process. It protects them from the environment 
and ensures the preservation of the properties during 
the entire “life cycle” of a drug - from manufacturing 
to consumption by a patient.
The packaging consists of a container, a product 
placed therein, a closure and labeling.
The main requirements to primary packaging 
are conventionally divided into:
1. Design.
Primary packaging should be designed to:
 ❖ protect a drug from adverse environmental 
conditions;
 ❖ protect against mechanical impacts;
 ❖ be tight and stable;
 ❖ protect against microbial contamination;
 ❖ provide metered or separated withdrawing of a 
drug;
 ❖ have first opening control;
 ❖ have good appearance and convenience in use;
 ❖ be safe.
2. Requirements of the materials.
Packaging materials used for the packing of 
medicinal products must be authorized for use by the 
Ministry of Public Health of Ukraine, and also com-
ply with specified requirements, not affect the stabili-
ty and pharmacological properties of drugs, not con-
tain carcinogenic and toxic components, heavy met-
als, arsenic and other harmful impurities in quan-
tities exceeding the standard norms, as well as dyes 
that are not permitted to use; should be free of any 
foreign smell and microbial contamination above the 
established norms. The packaging of sterile medical 
products should be composed of materials resistant 
to pre-sterilization, withstand sterilization methods 
specified by the manufacturing process and must not 
contain mechanical impurities.
3. The specific requirements for packaging are 
determined mainly by the chemical compo-
sition of a drug and its production process.
Containers for packaging of medicines con-
taining hygroscopic, volatile and oxidizing agents 
should provide moisture, vapor and gas barrier with-
in the relevant indicators of normative documents; 
for drugs of fatty base - should have low fat (oil) pene-
trability; for light sensitive drugs - should be opaque. 
For injection solutions, eye drops, on the contrary, 
packaging should be transparent to make inclusion 
control possible. 
4. General requirements for packaging (30):
 ❖ clarity of the texts printed on a packaging;
 ❖ availability of instructions for use;
 ❖ attractive color design;
 ❖ availability of the first opening control;
 ❖ safety of use;
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 ❖ absence of sharp corners and edges.
The additional requirements to primary pack-
aging for pharmaceuticals are regulated by norma-
tive documentation including:
 ❖ composition of the packaging material indicat-
ing, in particular, qualitative composition of the 
different parts of a package, as well as non-plas-
tic parts;
 ❖ description of a closing element (composition 
and test methods) including, if necessary, de-
scription of a waterproof and airtight seal;
 ❖ method of package opening and, if necessary, 
devices ensuring safety;
 ❖ container information (multidose or mono-
dose) and measuring devices;
 ❖ description of the closing element which pre-
vents opening of a container by children.
Considering all of the above-mentioned infor-
mation, the aim of this article was to study influence 
of primary packaging materials on the identification 
of medicines and the evaluation of their quality.
OBJECTS AND METHODS OF 
RESEARCH
Objects of this study were the primary packag-
es of randomly chosen drugs produced by some of 
the leading manufacturers in different forms. The 
subject of the study was the possibility of identifica-
tion of this drugs and the evaluation of their quality 
indicators.
Inspection analysis of the quality level of the re-
searched medicinal products was provided in the fol-
lowing steps (Fig. 1).
Stage 1. Checking of the accompanying docu-
ments for incoming goods.
The documentary analysis has the aim to evalu-
ate the commodity characteristics of the goods based 
on the information in the accompanying shipping 
documents. Checking the completeness of the ac-
companying documents (invoices, waybills, tax way-
bills, batch (lot) quality certificates, list of medici-
nal products and other documents confirming the 
amount and the quality of incoming goods) as well 
as the correctness of their drawing up. The authen-
ticity and correctness of the filled out documents are 
evaluated by the presence of the required data, sig-
natures, stamps of the supplying company, its name 
and address. In addition, cross-verification of the 
main characteristics of the goods specified in vari-
ous documents (invoices, batch and conformity cer-
tificates) and labeling is provided. 
Stage 2. Checking the range, quantity and 
quality of the goods specified in the accompanying 
documents and the ones actually received.
The assortment analysis of goods has the aim 
to verify their conformity to name, article, trade-
mark specified in the labeling and the accompany-
ing documents.
Checking the goods by their quantity is carried 
out by comparing those specified in the orders, ac-
companying shipping documents of the supplier and 
the ones actually received.
The quantity of products is counted in the units 
specified in the supply contracts.
Quality control is provided by comparing the 
quality of the incoming goods, their completeness, 
packaging and labeling with the requirements of 
the standards, as well as the contract terms and the 
data of supplier’s accompanying shipping documents 
confirming quality of these products (e.g., drug batch 
certificates).
Stage 3. Providing organoleptic (visual) con-
trol of the product packaging.
Fig. 1. Stages of quality level evaluation of the researched 
medicinal products.
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Packaging protects a product from the exter-
nal environment. Its integrity and state influence the 
quantity, quality and safety of the goods.
Packaging control includes a number of mea-
sures to check integrity, quality of primary and sec-
ondary packaging, and their compliance with the 
physical and chemical properties of the drugs.
Checking the integrity and quality of second-
ary packaging begins from a detection of unusu-
al sounds such as broken glass and others. Then at-
tention is paid to size, shape (top, sides and bottom, 
possible deformations and damages as a result of me-
chanical stress), conformity to storage conditions (el-
evated temperature, humidity, etc.), quality of the 
material from which the packaging is made and its 
print design (distinct markings, color characteristics, 
possible change of colors). The presence or absence 
of defects is checked: local discoloration, dirt, dents, 
cracks, damage, leakage of contents, signs of forg-
ery or unauthorized opening, presence or absence of 
protective signs or seals, sometimes visible only un-
der special lighting (e.g., UV), etc.
Primary packaging is checked for integrity of 
the container, presence of seals, first opening control, 
labeling.
Stage 4. Checking of product labeling.
Labeling is intended to identify products as 
well as to provide information about the manufac-
turer, qualitative and quantitative characteristics of 
a product. Special requirements are applied to label-
ing: distinct and well-defined text and images, vis-
ibility, compliance with the consumer properties of 
the goods, authenticity (the information given on a 
label must correspond to the quantity and quality of 
the goods), manufacturer’s name, country of origin 
and others.
During the checking process the information 
on the labeling is analyzed and it must be identi-
cal to that specified in the accompanying shipping 
documents.
When checking the labeling of medicinal prod-
ucts, attention should be paid to matching the drug 
batch number on the primary, secondary packag-
ing and the one in the accompanying shipping docu-
ments. It’s necessary to ensure that the manufactur-
ing of this drug batch has not been discontinued.
The labeling on the secondary packaging of a 
finished medicinal product includes: country of the 
manufacturer, manufacturer’s name, their trade-
mark and address, name of the finished medicinal 
product in Ukrainian and/or Russian and/or English 
and/or Latin, form of the medicine, quantity of the 
finished product, concentration (activity or dose), 
qualitative and quantitative composition of the in-
gredients, way of administration, batch number, ex-
piration date, registration number, storage condi-
tions, barcode.
Labeling on ampoules, syringe tubes and pi-
pettes includes the name of the finished product, 
concentration or activity, quantity of the drug, batch 
number, expiration date. The following should be 
indicated on a tube: the name of the drug, dose (or 
concentration or activity of the drug), batch num-
ber, expiration date, the proprietor of the registration 
certificate.
Labeling of drugs with Braille font: accord-
ing to the Order of the Ministry of Public Health of 
Ukraine № 722 dated 25.08.2010 “About approval of 
the labeling of medicinal products with Braille font”, 
which was enforced on 26.11.2010, requirements for 
drug labeling were introduced considering the Di-
rective of the European Parliament and Council of 
Europe N 2004/27/EC from 31.03.2004.
Braille marking is applied to the secondary 
packaging of medicinal products and should be pre-
sented in Ukrainian and by the applicant’s request in 
Russian or another language.
Braille marking includes:
 ❖ name of the drug (for drugs in one form and 
dose as well as for herbal preparations this is 
enough);
 ❖ dose of the active substance (if a drug is pro-
duced in multiple doses);
 ❖ form (if a drug is produced in multiple forms).
Stage 5. Checking the product barcode.
When analyzing barcodes of goods it’s neces-
sary to check:
1. Number of barcodes. Often, only one barcode 
type is applied to the packaging such as Eu-
ropean Article Numbering (EAN) or Univer-
sal Product Code (UPC). Use of two barcode 
types is acceptable if a manufacturer is reg-
istered in two associations. In this case, they 
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should be printed on opposite sides of the 
package.
2. Location of the barcode. The location of a 
barcode on a package (or a product) must 
conform to the requirements of the nation-
al standards.
Generally, it’s recommended to place the bar-
code mark on the back side of a package (product) in 
the lower right corner. It’s allowed to place it in the 
lower right quadrant of any other side of a packag-
ing. General Specifications GS1 show strict require-
ments: the minimum distance of a barcode (includ-
ing a stabilization zone) from any edge of a package 
(product) must be not less than 8 mm and not more 
than 102 mm.
The standard orientation of a barcode is hori-
zontal: the digits printed below the barcode should be 
oriented in the same direction as the text or graphic 
design of the packaging.
When a barcode is located on a curved surface, 
the angle between the tangents to the curved surfac-
es, one of which passes through the midpoint of a 
barcode and another one – through the outer edge of 
barcode limiting zone, should not exceed 30°.
A barcode should not be placed onto other la-
beling elements (text, images, perforations).
3. Check of the digits and their correctness is de-
termined by scanner or by calculation. A fail-
ure may indicate a technical error when typ-
ing a barcode or a falsification of a product.
4. Dimensions of the barcode. Codes recom-
mended for application onto the packaging of 
medicines are divided by their size in small, 
normal and large ones. The most commonly 
used standard size is 10 mm in height, 27 mm 
or 36 mm in length.
5. Color of barcode marks. A barcode should be 
black, blue, green or dark brown. Shades of 
red and yellow colors for bars are not allowed 
as they cannot be read by a scanner. Back-
ground color should be white but it can also 
be yellow or beige.
6. Print quality of the barcode. Bars should be 
uniform in color and contrast, without blurs 
or lighter spots inside. 
7. Compliance with the code list registered in 
the EAN association. The first two or three 
digits of a barcode should correspond to an 
EAN number assigned to the country. The 
origin and identification of a product man-
ufactured in a certain country should be 
checked. Non-compliance of these digits is a 
sign of product falsification.
Stage 6. Checking of the contents of the goods.
Checking for completeness means to verify the 
compliance of a set of the products to the list of indi-
vidual components specified in the operating manu-
als or related documents.
The term completeness includes the combina-
tion of elements forming a single product unit with 
certain consumer properties of the goods, and these 
elements are used as a whole but not separately.
When checking the completeness of the fin-
ished medical product, presence or absence of in-
structions (leaflets), dispensers and other devices for 
the use of this drug are verified.
Stage 7. Providing organoleptic (visual) con-
trol of a product.
General organoleptic characteristics are 
as follows: appearance, taste, smell, consistency. 
Appearance is the comprehensive parameter in-
cluding shape, color, state of a surface. Appear-
ance is not only easy to check but also one of 
the most important criteria for a comprehensive 
evaluation of product quality. It is the #rst stage 
of product identi#cation by manufacturers, sell-
ers and buyers. Organoleptic control of medi-
cine forms is carried out using the parameter 
in monographs “Appearance” or “Description” 
(9,31,32).
Requirements for tablets.
The evaluation of tablet quality begins with a 
check of their appearance (organoleptic properties) 
which is affected by the following factors during pro-
duction: compressing conditions, adhesion and co-
hesion properties of the mass to be compressed, its 
moisture content, particle size distribution, surface 
and precision of the press tools, method of coating, 
etc.
The following defects should be absent on tab-
lets: protrusions (projections on the surface or ad-
hering powder particles); hollows (craters, crumbled 
parts of tablets); dirt or dust; marbling (non-uni-
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form color, local color changes); chips (different lay-
ers in the tablets, reduced thickness); agglutination 
(sticking of tablets together or their binding to dam-
aged surfaces); crumbling; deformations (non-round 
shape); scratches; coating defects (non-uniform coat-
ing surface, varying thickness, shift of the core from 
center).
Tablets should have a round or other shape with 
flat or biconvex surfaces, unbroken edges; the surface 
should be smooth and uniform in color unless oth-
erwise indicated in the reference documentation (32).
Requirements for suppositories.
Depending on the structure and characteristics 
of the body cavities suppositories may have various 
geometric shapes and sizes. They are divided into 
rectal, vaginal suppositories and sticks. Rectal sup-
positories are administered into the rectum, vaginal 
ones – into the vagina, and sticks – into urinary and 
other canals (cervix, ear canal, fistulas and wounds). 
All suppositories, especially rectal and urethral ones, 
should have sufficient hardness allowing them to 
overcome the resistance of tissues and sphincters; 
otherwise they would become deformed and their 
use becomes impossible.
Suppositories should have a proper uniform 
shape, smooth consistency and sufficient hardness, 
which provides ease of use, their color and smell 
should correspond to the properties of the ingredi-
ents. Uniform consistency is checked visually for ab-
sence of foreign materials or coarse surfaces. Pres-
ence of air bubbles or funnel-shaped hollows are 
acceptable.
Requirements for eye drops and injection 
solutions.
Eye drops and injection solutions should not 
contain mechanical impurities visible with a na-
ked eye. They should be transparent, sterile, isoton-
ic and stable, suspension drops may form a precipi-
tate which should be re-suspended easily by agitation 
forming a stable suspension. To control visible parti-
cles, 60 ampoules from a batch are randomly chosen. 
Presence of visible mechanical impurities is allowed 
in no more than one item (31). 
Stage 8. Preparing the documentation for the 
reception of the goods. 
Based on the results from the inspection anal-
ysis, commission members prepare corresponding 
documents about the reception of the goods by quan-
tity, quality and completeness. These acts are com-
piled separately by each supplier and for each batch 
of goods received according the accompanying ship-
ping documents.
To provide a study of quality indicators of some 
medicines to conform them to the requirements of 
the inspection analysis, we took randomly 65 sam-
ples of drugs produced by different manufacturers in 
various forms. These drugs are presented in the Table 
1. Their compliance with the established organolep-
tic characteristics was determined by the procedures 
specified in current reference documents, pharmaco-
poeian monographs and others.
Sample 
number
Form Primary packaging Name of the product
and the manufacturer
Sandoz, Lek, Poland, Austria, Romania, Slovenia
1 tablets non-transparent
blister pack
















Dicinon 250 mg (Lek Pharmaceutical Compa-
ny, Slovenia)
Table 1. Test samples of medicines
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6 tablets transparent
blister pack








Persen (Lek Pharmaceutical Company, Slovenia)
Alcon-Couvreur, Belgium
9 eye drops white polymeric
non-transparent vial
Tobrex 0.3 %, 5 ml 
10 eye drops white polymeric
non-transparent vial
Quinax 0.015 %, 15 ml  
11 eye drops white polymeric
non-transparent vial
Betoptic S 0.25 %, 5 ml  
12 eye drops white polymeric
non-transparent vial
Azopt 1 %, 5 ml  
13 eye drops polymeric non-trans-parent 
dropper-vial 
Maxitrol 5 ml 
14 eye drops polymeric transparent 
dropper-vial
Maxidex 0.1%, 5 ml  




Ampril 2.5 mg, 5 mg, 10 mg
17 tablets non-transparent
blister pack
Amlessa 4 mg / 5 mg, 4 mg /10 mg,
8 mg / 5 mg, 8 mg / 10 mg  
18 tablets non-transparent
blister pack
Bisoprolol 5 mg, 10 mg
19 tablets non-transparent
blister pack
Roxera 10 mg, 20 mg
20 tablets non-transparent
blister pack
Atoris 10 mg, 20 mg, 30 mg, 40 mg
21 tablets non-transparent
blister pack




Nolpasa 20 mg, 40 mg
Continuation of the Table 1.  
23 tablets non-transparent
blister pack
Enap 2.5 mg, 5 mg, 10 mg, 20 mg
24 tablets non-transparent
blister pack
Enap Н 10 mg
25 tablets non-transparent
blister pack
Enap HL 10 mg, 20 mg
26 tablets transparent
blister pack
Vasylil 10 mg, 20 mg
27 tablets transparent
blister pack
Valsakor 80 mg, 160 mg, 320 mg
28 tablets transparent
blister pack
Valsakor HD 160 mg / 25 mg, 
320 mg / 25 mg
29 tablets transparent
blister pack
Lorista 50 mg, 100 mg  
68 
Scripta Scientifica Pharmaceutica, vol. 3, No. 1, 2016, pp. 60-72 
Medical University of Varna
Effect of the Material of Primary Packaging Containers on Providing Visual Inspection of Pharmaceutical Products
30 tablets transparent
blister pack
Lorista H 50 mg / 2.5 mg
31 tablets transparent
blister pack
Lorista HD 100 mg /25 mg
32 tablets transparent
blister pack
Cyprinol 250 mg, 500 mg, 750 mg
Berlin-Chemie / Menarini Pharma Gmbh (representative, Germany)
33 tablets non-transparent
blister pack
Lekramen 10 mg, 20 mg
34 tablets non-transparent
blister pack
Berlipril 5 mg, 10 mg, 20 mg
35 tablets non-transparent
blister pack
L-thyroxine 75, L-thyroxine 50,       L-thyroxine 
125, L-thyroxine 100,   L-thyroxine 150  
36 tablets non-transparent
blister pack
Mezym-forte 10000, 20000  
37 tablets non-transparent
blister pack
Dicloberl 50 mg  
38 tablets non-transparent
blister pack
Berlithion 300 mg 
39 tablets transparent
blister pack
Corvitol 50 mg, 100 mg 
40 tablets transparent
blister pack
Trifas 10 mg, Trifas–COR 5 mg 
41 tablets transparent
blister pack
Nebilet 5 mg 
42 tablets transparent
blister pack
Falimint 25 mg 
43 tablets transparent
blister pack
Siofor 500 mg, 850 mg, 1000 mg 
Pharmak, Ukraine
44 eye drops white polymeric
non-transparent vial
Vial 0.05 % 10 ml  
45 eye drops white polymeric
non-transparent vial
Vial light 0.5 % 10 ml  
Continuation of the Table 1.  
46 eye/ear drops white polymeric
non-transparent vial
Cypropharm 10 ml  
47 eye drops white polymeric
non-transparent vial
Ophthymol 5 ml, 10 ml 
48 eye drops white polymeric
non-transparent vial






blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film
Anaesthezol №5
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RESULTS AND DISCUSSION
Results of inspection analysis of medicinal 
products studied in the paper are presented in the 
Table 2.
According to the data in the Table 2 we can con-
clude that all samples passed the first 6 stages of in-




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film
Tamistol 15 mg №5




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film




blister pack with PVC-film
Glycerol 2110 mg, 1240 mg №10
Number 
of stage
Parameter to be tested Results
1 Accompanying documents for the incoming goods Conforms to the requirements
2 Range, quantity and quality of the goods specified in the ac-
companying documents and the ones actually received
Conforms to the requirements
3 Organoleptic (visual) control of the product packaging Conforms to the requirements
4 Product labeling Conforms to the requirements
5 Product barcode Conforms to the requirements
6 Contents of the goods Conforms to the requirements
7 Organoleptic (visual) control of the drugs Samples (4-8, 14-15, 26-32, 39-43) 
satisfy the requirements.
Samples (1 - 3, 9 - 13, 16- 25, 33 
- 38, 44 - 65) cannot be visual-
ly evaluated for quality of the 
formulation.
Table 2. Results of the inspection analysis of the studied samples
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The possibility of visual control of the medi-
cines (stage 7) depends, first of all, on the properties 
of the primary packaging containers, namely, their 
transparency. As it can be seen from our results, 46 
samples out of 65 (or 71%) cannot be visually identi-
fied and their appearance is impossible to check be-
cause of the opacity of the containers. When it comes 
to different forms 53% of studied tablet drugs, 88% of 
the eye drops and 100% of the suppositories cannot 
be evaluated visually. Analyzing drugs from different 
manufacturers we found that Sandoz and Lek pro-
duce 3 brand names (tablets) in non-transparent blis-
ter packs out of the 8 ones researched, Alcon-Couv-
reur (eye drops) – 5 out of 7, Кrка Novo-Mesto (tab-
lets) – 10 out of 17, Berlin-Chemie (tablets) – 6 out 
of 11, Pharmak, Ukraine (eye drops) – all 5 of them, 
Lekchim-Kharkov, Ukraine (suppositories) – all 8 of 
them, Nizhpharm, Russia ((suppositories) – all 9.
This means that we are not able to properly 
evaluate such drugs while placed into primary pack-
aging. Even the containers of most of the eye drops 
were made from opaque plastic, whereas according 
to the GMP requirements they should be as trans-
parent as possible. 
CONCLUSIONS
Based on the inspection analysis of the accom-
panying documentation, quantity, packaging, label-
ing, barcodes and completeness of randomly select-
ed 65 drug samples produced by different manufac-
turers in tablet, drop and suppository forms, we can 
conclude that all of them complied with the require-
ments of the normative documentation at the first 6 
stages of inspection. However, it was impossible to 
evaluate 71% of the studied samples by the parame-
ter “Appearance” because of the non-transparence of 
their primary containers. The results of the research 
will play an important role in the development of ad-
vanced kinds of packaging which can allow proper 
identification and evaluation of drug quality in vari-
ous forms. 
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